Emerging as one of the most promising therapeutic modalities in recent years, antibody-drug conjugates (ADCs) are experiencing a renaissance in oncology.
By combining the precision targeting of monoclonal antibodies with the potent cell-killing ability of small-molecule drugs, ADCs offer a powerful approach to treating cancer. However, their development is anything but straightforward.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.